Navigation Links
Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
Date:6/9/2008

ng statements regarding the development, therapeutic potential, efficacy and safety of AZ-002. Any statement describing a product candidate or Alexza's goals, expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings: "Failure or delay in commencing or completing clinical trials for our product candidates could harm our business" and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them". Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
2. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
3. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
6. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
7. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
8. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
9. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
10. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
11. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... DUBLIN , June 02, 2015 ... the addition of the "The Future of ... As they are in a desperate need ... and low cost, drug companies have been increasingly ... enhance their productivity while constantly streamlining their internal ...
(Date:6/3/2015)... , June 3, 2015  Varian Medical Systems (NYSE: ... the treatment of cancer, is expanding in the Middle ... entity in Saudi Arabia . Varian Medical ... Seif Development Group, was officially launched today at a ceremony ... Wilson. "This move represents the next step ...
(Date:6/3/2015)... June 02, 2015 Research and Markets ... the "2015 Strategies in the US Tumor ... Highlights of the Report Include ... tumor marker testing market. , Major issues ... as key economic, regulatory, demographic, social and technological ...
Breaking Medicine Technology:The Future of Pharmaceutical Outsourcing: 2015 Report 2Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2United States Strategies in the Tumor Marker Testing Market 2015 2
... Colo., Oct. 18, 2011 SomaLogic, Inc., announced today ... with Novartis to use its unique proprietary proteomics technology ... "We are excited by this opportunity to ... robust biomarkers, validate novel drug targets, and even develop ...
... Oct. 18, 2011 ... (Nasdaq: HOLX ), a leading developer, manufacturer and ... products dedicated to serving the healthcare needs of women, announced ... cleared the Company,s Trident specimen radiography system. The ...
Cached Medicine Technology:SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development 2FDA Clears Hologic's Specimen Radiography System 2FDA Clears Hologic's Specimen Radiography System 3FDA Clears Hologic's Specimen Radiography System 4
(Date:6/3/2015)... Dr. Steven Reisman, a nationally recognized cardiologist and Director ... located in NYC, announced today the expansion of same day ... cases, depending on the level of care a patient needs ... be seen by a cardiologist that same day. , Dr. ... ensure that people who have an urgent need to be ...
(Date:6/3/2015)... Alberto Grignolo, PhD, will be honored with ... DIA’s Global Inspire Award program recognizes the organization’s outstanding ... to service on a global scale. , ... recognizes one DIA member for meritorious service through a ... to foster innovation to improve health and well-being worldwide. ...
(Date:6/3/2015)... 2015 Justina Molzon, MS Pharm, JD ... DIA’s upcoming Annual Meeting. DIA’s Global Inspire Award program ... of excellence, and commitment to service on a global ... in Service Award that recognizes the “Member of the ... volunteer and who has contributed to the advancement of ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Visual ... Analytics solutions, today announced the launch of the ... (DSX) for SAP® BusinessObjects™ Design Studio. The Design ... visualization capabilities and advanced functionalities into their dashboarding ... DSX suite, Visual BI is adding key components ...
(Date:6/3/2015)... For the fourth time in less than a ... advertising agency, has been honored by a respected independent organization—this ... has been selected as a Semi-Finalist for the 2015 “Small ... at a luncheon sponsored by Adcock Financial Group and Simpson ... , “This luncheon will include important information about the next ...
Breaking Medicine News(10 mins):Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 3Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3Health News:My Classified Ads Has Been Selected as a Semi-Finalist for the 2015 ‘Small Business of the Year’ Awards 2Health News:My Classified Ads Has Been Selected as a Semi-Finalist for the 2015 ‘Small Business of the Year’ Awards 3
... , A discovery made by researchers at McGill University ... at Montreal,s Jewish General Hospital offers new hope for the ... study published in the Journal of Biological Chemistry ... Han and postdoctoral fellows Hamid Qureshi and Yifan Lu, report ...
... Mass.)Potentially modifiable post-fracture complications, including pneumonia and pressure ... death among nursing home residents who have suffered ... conducted by scientists at the Institute for Aging ... reduce pressure ulcers and pneumonia may help reduce ...
... leading national provider of eye care services, announced the opening ... number of stores in the area to eight. The ... Village in Kissimmee on May 1. The eyewear chain ... Visionworks is a full-service optical retail center that ...
... adults 60 and over may qualify for a little extra ... Act, benefits have risen for the first time in years. ... of groceries and Medicare premiums, if people invest an hour ... for Michigan,s Coordinated Access to Food for the Elderly. MiCAFE ...
... Reach $500 Million by 2014PRINCETON, N.J., May 22 ... federal funds next year and more than $500 million ... rules proposed to take effect in October, according to ... Economics department examined the impact of three provisions under ...
... Looking for efficient anti-tumor drugs is a hot ... flavonoid, has been reported to have many different ... and clear anxiolytic effect. However, Chrysin is limited ... absorption in the intestine and rapid in vivo ...
Cached Medicine News:Health News:Alzheimer's discovery could bring early diagnosis, treatment closer 2Health News:Institute for Aging Research finds modifiable hip fracture complications contribute to mortality 2Health News:National Eyewear Chain Visionworks Opens Two New Stores in Orlando Market 2Health News:A Bright Spot - Financial Help for Seniors 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 3Health News:A potential drug for liver carcinoma 2
Antigenic Total Protein S, ELISA Method...
... Protein C Activity by STA© ... of Protein C; highly purified ... venom for specific activation of ... activator selected specially for protein ...
Immuno-turbidimetric Assay for Antithrombin III Antigen. Suspension of microlatex particles coated with specific antibodies....
Immuno-turbidimetric Assay for Protein S Antigen. Suspension of microlatex particles coated with specific antibodies....
Medicine Products: